Browse our latest Microbiology and Infectious Disease articles

Reducing vaccine development time from 12 months to 6 reduces forecasting error by 25%, while reducing lags in genome sequence submission reduces uncertainty of current clade frequencies by 50%.

The enteric bacterial Shigella secretes a virulence factor that degrades the pivotal human defense protein RNF213, thereby protecting cytosolic bacteria from interferon-driven ubiquitylation and associated innate immunity.

Integrative analyses uncover RBMX2 as a pivotal mediator that bridges Mycobacterium bovis infection to epithelial–mesenchymal transition and tumor progression in the lung.

The development of new small molecules demonstrates how pharmacologic inhibition of the coronavirus macrodomain restores innate immunity, leading to reduced viral replication and improved outcomes in severe infection.

Unraveling mechanisms underlying post-acute SARS-CoV-2 sequelae (long COVID) and finding therapeutic solutions require a full understanding of the causative role of SARS-CoV-2 persistence and/or infection with other microorganisms, which may be pre-existing, concurrent, or subsequent to acute COVID-19.